Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,498
  • Shares Outstanding, K 59,466
  • Annual Sales, $ 0 K
  • Annual Income, $ -73,790 K
  • EBIT $ -69 M
  • EBITDA $ -72 M
  • 60-Month Beta 1.00
  • Price/Sales 5.68
  • Price/Cash Flow N/A
  • Price/Book 0.60

Options Overview Details

View History
  • Implied Volatility 226.61% ( -212.01%)
  • Historical Volatility 190.49%
  • IV Percentile 69%
  • IV Rank 31.32%
  • IV High 700.04% on 12/09/24
  • IV Low 10.70% on 07/15/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,530
  • Volume Avg (30-Day) 1,336
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 35,890
  • Open Int (30-Day) 34,096

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -0.38
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4900 +13.42%
on 12/19/24
2.3900 -29.29%
on 11/21/24
-2.1300 (-55.76%)
since 11/20/24
3-Month
1.4900 +13.42%
on 12/19/24
5.3899 -68.65%
on 11/11/24
-2.0000 (-54.20%)
since 09/20/24
52-Week
1.4900 +13.42%
on 12/19/24
6.8500 -75.33%
on 02/27/24
-0.0500 (-2.87%)
since 12/20/23

Most Recent Stories

More News
Pyxis Oncology Prioritizes Development of Lead Asset PYX-201 Following Promising Phase 1 Results

Pyxis Oncology prioritizes development of PYX-201, an antibody-drug conjugate showing promise in treating solid tumors, including HNSCC.Quiver AI SummaryPyxis Oncology, Inc. is reallocating its resources...

PYXS : 1.6900 (+9.74%)
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

PYXS : 1.6900 (+9.74%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.8310 (-6.36%)
PYXS : 1.6900 (+9.74%)
RPTX : 1.3200 (unch)
IMRX : 2.00 (+8.70%)
CVM : 0.7299 (-4.60%)
ONC.TO : 1.19 (-9.16%)
Stocks Rise Before the Open With U.S. Economic Data in Focus, Nvidia Slips on Disappointing Forecast

December S&P 500 E-Mini futures (ESZ24) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.09% this morning as investors looked ahead to a raft of U.S. economic data that could provide...

TGT : 131.48 (+0.81%)
EVTC : 33.61 (+0.03%)
NVDA : 134.70 (+3.08%)
DE : 432.49 (+1.37%)
PYXS : 1.6900 (+9.74%)
INTU : 643.39 (+1.01%)
SNOW : 166.29 (+1.27%)
JD-.LN : 95.450 (-1.70%)
NQZ24 : 20,947.98s (-0.78%)
FN : 221.26 (-0.66%)
CPRT : 58.22 (-0.39%)
QCOM : 152.89 (+1.66%)
Pyxis Oncology Reports Promising Phase 1 Clinical Data for PYX-201 in Multiple Solid Tumors and Announces Collaboration with Merck to Evaluate Combination Therapy

PYX-201 shows promising efficacy and safety in solid tumors, with expansion trials set to begin in 2025.Quiver AI SummaryPyxis Oncology announced positive preliminary results from a Phase 1 dose escalation...

PYXS : 1.6900 (+9.74%)
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

PYXS : 1.6900 (+9.74%)
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

PYXS : 1.6900 (+9.74%)
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

PYXS : 1.6900 (+9.74%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
PYXS : 1.6900 (+9.74%)
AZN : 65.35 (+1.41%)
LLY : 767.76 (+1.35%)
MRUS : 41.85 (-0.57%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.19 (-9.16%)
ONCY : 0.8310 (-6.36%)
PYXS : 1.6900 (+9.74%)
AZN : 65.35 (+1.41%)
LLY : 767.76 (+1.35%)
MRUS : 41.85 (-0.57%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.9383
2nd Resistance Point 1.8167
1st Resistance Point 1.7533
Last Price 1.6900
1st Support Level 1.5683
2nd Support Level 1.4467
3rd Support Level 1.3833

See More

52-Week High 6.8500
Fibonacci 61.8% 4.8025
Fibonacci 50% 4.1700
Fibonacci 38.2% 3.5375
Last Price 1.6900
52-Week Low 1.4900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar